Longboard Pharmaceuticals (LBPH) Revenue & Revenue Breakdown
Longboard Pharmaceuticals Revenue Highlights
00
Longboard Pharmaceuticals Revenue by Period
Longboard Pharmaceuticals Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | - |
Longboard Pharmaceuticals Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | - | 100.00% |
2024-06-30 | - | 100.00% |
2024-03-31 | - | -100.00% |
2023-12-31 | $8.00K | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | - |
Longboard Pharmaceuticals Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
HOWL | Werewolf Therapeutics | $19.94M | $1.14M |
IKNA | Ikena Oncology | $9.16M | - |
STOK | Stoke Therapeutics | $8.78M | $4.89M |
ASMB | Assembly Biosciences | $7.16M | $6.84M |
MOLN | Molecular Partners | $7.04M | $2.74M |
MNOV | MediciNova | $1.00M | - |
ANEB | Anebulo Pharmaceuticals | - | - |
DSGN | Design Therapeutics | - | - |
CCCC | C4 Therapeutics | - | - |
LBPH | Longboard Pharmaceuticals | - | - |
NXTC | NextCure | - | - |
DBTX | Decibel Therapeutics | - | - |
TIL | Instil Bio | - | - |
GRPH | LENZ Therapeutics | - | - |
CYT | Cyteir Therapeutics | - | - |
CELC | Celcuity | - | - |
SNSE | Sensei Biotherapeutics | - | - |
MACK | Merrimack Pharmaceuticals | - | - |
GLUE | Monte Rosa Therapeutics | - | $4.70M |
EWTX | Edgewise Therapeutics | - | - |
NUVB | Nuvation Bio | - | $727.00K |
CSBR | Champions Oncology | - | - |